# The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension

Study · id `cardio:ct-nct07359599` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07359599](<https://clinicaltrials.gov/study/NCT07359599>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07359599

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 306 participants.

## Technical summary

Registry record NCT07359599. Randomized; quadruple masking; primary purpose supportive care. Start 2026-01-27 (actual); primary completion 2028-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose supportive care
- Phase: Phase 4
- Enrolled: 306 participants (planned count; ClinicalTrials.gov record NCT07359599, source copy `cardio:ctgov-nct07359599-2026-01-30`, retrieved 2026-10-31)
- Started: 2026-01-27 (actual) (ClinicalTrials.gov record NCT07359599, source copy `cardio:ctgov-nct07359599-2026-01-30`, retrieved 2026-10-31)
- Primary completion: 2028-07 (anticipated) (ClinicalTrials.gov record NCT07359599, source copy `cardio:ctgov-nct07359599-2026-01-30`, retrieved 2026-10-31)
- Completion: 2028-10 (anticipated) (ClinicalTrials.gov record NCT07359599, source copy `cardio:ctgov-nct07359599-2026-01-30`, retrieved 2026-10-31)
- Countries: Belgium (ClinicalTrials.gov record NCT07359599, source copy `cardio:ctgov-nct07359599-2026-01-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07359599-2026-01-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension
- Acronym: IRON-PH
- Condition: Pulmonary Hypertension
- Condition: Iron Deficiency
- Intervention (Drug): Ferric Carboxymaltose (FCM)
- Intervention (Drug): Sodium Chloride (NaCl) 0.9 %
- Lead sponsor: Ziekenhuis Oost-Limburg
- Lead sponsor class: OTHER
- Collaborator: Federal Knowledge Centre (KCE)
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Ziekenhuis Oost-Limburg (`cardio:org-ziekenhuis-oost-limburg`)

## Provenance

Content hash: e2d08c6edbeda138331646872ccfd54f9a7e90e94d605bea025836f8067d9aa6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
